Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study
In: Hypertension Research, Jg. 45 (2022-01-21), S. 824-833
Online
unknown
Zugriff:
This phase III study assessed the efficacy and safety of sacubitril/valsartan compared with those of olmesartan in Japanese patients with essential hypertension. Patients (n = 1161, aged ≥20 years) with mild to moderate hypertension (mean sitting systolic blood pressure [msSBP] ≥150 to n = 387), sacubitril/valsartan 400 mg (n = 385), or olmesartan 20 mg (n = 389) once daily for 8 weeks. The primary assessment was a reduction in msSBP from baseline with sacubitril/valsartan 200 mg vs. olmesartan 20 mg at Week 8. Secondary assessments included msSBP reduction with sacubitril/valsartan 400 mg vs. olmesartan at Week 8 and reductions in mean sitting diastolic blood pressure (msDBP), mean sitting pulse pressure (msPP), and overall blood pressure (BP) control rate for all treatment groups at Week 8. Sacubitril/valsartan 200 mg provided a significantly greater reduction in msSBP from baseline than olmesartan at Week 8 (between-treatment difference: −5.01 mmHg [95% confidence interval: −6.95 to −3.06 mmHg, P vs. olmesartan (P
Titel: |
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study
|
---|---|
Autor/in / Beteiligte Person: | Hiromi, Rakugi ; Kazuomi, Kario ; Masako, Yamaguchi ; Takayoshi, Sasajima ; Hiromi, Gotou ; Jack, Zhang |
Link: | |
Zeitschrift: | Hypertension Research, Jg. 45 (2022-01-21), S. 824-833 |
Veröffentlichung: | Springer Science and Business Media LLC, 2022 |
Medientyp: | unknown |
ISSN: | 1348-4214 (print) ; 0916-9636 (print) |
DOI: | 10.1038/s41440-021-00819-7 |
Schlagwort: |
|
Sonstiges: |
|